The role of Rifaximine-α in traveler’s diarrhea therapy
Traveler’s diarrhea (TD) is an acute, self-limited disease, caused by a wide array of germs that possess intestinal tropism. Among the 12 million people travelling annually to tropical or subtropical areas, 30% up to 70% are affected by TD. A single episode of diarrhea can severely impair, sometimes...
Main Authors: | , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Amaltea Medical Publishing House
2016-03-01
|
Series: | Romanian Journal of Infectious Diseases |
Subjects: | |
Online Access: | https://rjid.com.ro/articles/2016.1/RJID_2016_1_Art-06.pdf |
id |
doaj-520ec737c43c4ecd98a9d85aeae3ef6f |
---|---|
record_format |
Article |
spelling |
doaj-520ec737c43c4ecd98a9d85aeae3ef6f2021-09-08T14:38:54ZengAmaltea Medical Publishing HouseRomanian Journal of Infectious Diseases1454-33892069-60512016-03-01191303610.37897/RJID.2016.1.6The role of Rifaximine-α in traveler’s diarrhea therapyVictoria Aramă0Ioan Diaconu1Laurenţiu Stratan2Sorin Ştefan Aramă3Institutul Naţional de Boli Infecţioase „Prof. Dr. Matei Balş“, Bucureşti; Universitatea de Medicină şi Farmacie „Carol Davila“, BucureştiInstitutul Naţional de Boli Infecţioase „Prof. Dr. Matei Balş“, BucureştiInstitutul Naţional de Boli Infecţioase „Prof. Dr. Matei Balş“, BucureştiInstitutul Naţional de Boli Infecţioase „Prof. Dr. Matei Balş“, Bucureşti; Universitatea de Medicină şi Farmacie „Carol Davila“, BucureştiTraveler’s diarrhea (TD) is an acute, self-limited disease, caused by a wide array of germs that possess intestinal tropism. Among the 12 million people travelling annually to tropical or subtropical areas, 30% up to 70% are affected by TD. A single episode of diarrhea can severely impair, sometimes severe, the performance of special categories of travelers, like sportsmen, business people, or diplomats in specific missions. The disease has an equal distribution among sexes, occurring with a higher frequency among the youth. The Enterotoxigenic E.coli is the main pathogen incriminated in 80 to 90% of TD’cases.Recent international infectious disease or traveler medicine guidelines are recommending Rifaximine-α(RFX) as the first therapeutical option with the highest level of recommendation and evidence (IA) in treating or preventing non-invasive forms of TD. The normal daily dosage in these cases is 800 mg of RFX for at least 3 days. RFX is a non-absorbable (intestinal) antibiotic which has clinically proven its high rate of success regarding its safety and efficacy in treating and preventing TD. Referring to TD’s prevention, it must be mentioned that even though antibiotic prophylaxis is not routinely recommended while travelling (at least in cases of more than 3 weeks of travel), this approach should be serious taken into consideration for several types of high risk traveler patients who present at least one of the following conditions: immunodeficiency, chronic inflammatory intestinal diseases, kidney failure or diabetes mellitus. But even there are or not real reasons in recommending antibiotic prophylaxis, Rifaximine-α should not miss from any personal first-aid traveler-kit.https://rjid.com.ro/articles/2016.1/RJID_2016_1_Art-06.pdftraveler’s diarrhearifaximine-αantibiotic therapyantibiotic prophylaxisnormix |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Victoria Aramă Ioan Diaconu Laurenţiu Stratan Sorin Ştefan Aramă |
spellingShingle |
Victoria Aramă Ioan Diaconu Laurenţiu Stratan Sorin Ştefan Aramă The role of Rifaximine-α in traveler’s diarrhea therapy Romanian Journal of Infectious Diseases traveler’s diarrhea rifaximine-α antibiotic therapy antibiotic prophylaxis normix |
author_facet |
Victoria Aramă Ioan Diaconu Laurenţiu Stratan Sorin Ştefan Aramă |
author_sort |
Victoria Aramă |
title |
The role of Rifaximine-α in traveler’s diarrhea therapy |
title_short |
The role of Rifaximine-α in traveler’s diarrhea therapy |
title_full |
The role of Rifaximine-α in traveler’s diarrhea therapy |
title_fullStr |
The role of Rifaximine-α in traveler’s diarrhea therapy |
title_full_unstemmed |
The role of Rifaximine-α in traveler’s diarrhea therapy |
title_sort |
role of rifaximine-α in traveler’s diarrhea therapy |
publisher |
Amaltea Medical Publishing House |
series |
Romanian Journal of Infectious Diseases |
issn |
1454-3389 2069-6051 |
publishDate |
2016-03-01 |
description |
Traveler’s diarrhea (TD) is an acute, self-limited disease, caused by a wide array of germs that possess intestinal tropism. Among the 12 million people travelling annually to tropical or subtropical areas, 30% up to 70% are affected by TD. A single episode of diarrhea can severely impair, sometimes severe, the performance of special categories of travelers, like sportsmen, business people, or diplomats in specific missions. The disease has an equal distribution among sexes, occurring with a higher frequency among the youth. The Enterotoxigenic E.coli is the main pathogen incriminated in 80 to 90% of TD’cases.Recent international infectious disease or traveler medicine guidelines are recommending Rifaximine-α(RFX) as the first therapeutical option with the highest level of recommendation and evidence (IA) in treating or preventing non-invasive forms of TD. The normal daily dosage in these cases is 800 mg of RFX for at least 3 days. RFX is a non-absorbable (intestinal) antibiotic which has clinically proven its high rate of success regarding its safety and efficacy in treating and preventing TD.
Referring to TD’s prevention, it must be mentioned that even though antibiotic prophylaxis is not routinely recommended while travelling (at least in cases of more than 3 weeks of travel), this approach should be serious taken into consideration for several types of high risk traveler patients who present at least one of the following conditions: immunodeficiency, chronic inflammatory intestinal diseases, kidney failure or diabetes mellitus. But even there are or not real reasons in recommending antibiotic prophylaxis, Rifaximine-α should not miss from any personal first-aid traveler-kit. |
topic |
traveler’s diarrhea rifaximine-α antibiotic therapy antibiotic prophylaxis normix |
url |
https://rjid.com.ro/articles/2016.1/RJID_2016_1_Art-06.pdf |
work_keys_str_mv |
AT victoriaarama theroleofrifaximineaintravelersdiarrheatherapy AT ioandiaconu theroleofrifaximineaintravelersdiarrheatherapy AT laurentiustratan theroleofrifaximineaintravelersdiarrheatherapy AT sorinstefanarama theroleofrifaximineaintravelersdiarrheatherapy AT victoriaarama roleofrifaximineaintravelersdiarrheatherapy AT ioandiaconu roleofrifaximineaintravelersdiarrheatherapy AT laurentiustratan roleofrifaximineaintravelersdiarrheatherapy AT sorinstefanarama roleofrifaximineaintravelersdiarrheatherapy |
_version_ |
1717762363126448128 |